Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 71,346,495 | 60,243,416 | 59,023,034 | 62,867,601 | 60,664,155 | 314,144,701 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 71,346,495 | 60,243,416 | 59,023,034 | 62,867,601 | 60,664,155 | 314,144,701 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 28,272,944 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 285,871,757 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 71,346,495 | 60,243,416 | 59,023,034 | 62,867,601 | 60,664,155 | 314,144,701 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 933,027 | 994,910 | 729,749 | 945,520 | 1,174,418 | 4,777,624 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 8,553,010 | 6,781,431 | 8,229,643 | 9,656,398 | 6,105,766 | 39,326,248 |
| 11 | Total support. Add lines 7 through 10 | 358,248,573 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2020 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2020 |
(iii) Distributable Amount for 2020 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2020 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2020: | ||||
| a From 2015....... | ||||
| b From 2016....... | ||||
| c From 2017....... | ||||
| d From 2018....... | ||||
| e From 2019....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2020 distributable amount | ||||
|
i
Carryover from 2015 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2020 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2020 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2020, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2020. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2021. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2016..... | ||||
| b Excess from 2017..... | ||||
| c Excess from 2018..... | ||||
| d Excess from 2019..... | ||||
| e Excess from 2020..... | ||||
| Facts And Circumstances Test |
|---|
| Part II Section B Line 10 2020 Other Income of 6,105,766 is comprised of 5,569,393 of Clinical Research Program revenue, 430,308 of External Core income, and 106,065 of miscellaneous income. |
| Return Reference | Explanation |
|---|
| Software ID: | 20011406 |
| Software Version: | 20.0.2.0 |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| Form 990, Part III, Line 1 | Benaroya Research Institute at Virginia Mason BRI is one of the few research institutes in the world devoted to finding causes and cures for autoimmune disease and other diseases of the immune system including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, inflammatory bowel disease, cancers, allergies and infectious diseases. BRI is affiliated with the Virginia Mason Health System, which provides governance oversight, and development support through the Virginia Mason Foundation. BRIs bold mission is to predict, prevent, reverse and cure diseases of the immune system to achieve our vision of a healthy immune system for everyone. BRI is led by President Jane H. Buckner, MD, and Executive Director/COO Margaret McCormick, PhD. Discoveries at BRI are accelerated by our talented researchers, collaborative culture and application of new technologies and data analytics in a quest to understand what can cause the immune system to fall out of balance and what we can do to restore it to health. To that end, scientific activities are organized into four Centers of Discovery, a model that allows for knowledge sharing and for each Center and core lab to build on discoveries from individual labs 1 Fundamental Immunology, directed by Daniel Campbell, PhD 2 Translational Immunology, directed by Karen Cerosaletti, PhD 3 Interventional Immunology, directed by Carla Greenbaum, MD and 4 Systems Immunology, directed by Peter Linsley, PhD. In 2020 we recruited and integrated three new investigators into our institute Hamid Balouri, PhD, and John Ray, PhD into the Center for Systems Immunology and Carmen Mikacenic, MD, into the Center for Translational Immunology. In the year 2020, our vision of achieving a healthy immune system for every person took on a new urgency as we pivoted our expertise and research skills to help solve the mysteries of COVID-19. With our clinical research expertise and the help of many volunteers, we served as a trial site for testing the Pfizer vaccine for COVID -19 as well as a trial site for the drug remdesivir. We were also able to complete volunteer enrollment and push forward our Sound Life Project to help us understand what constitutes a healthy immune system and what causes it to move from health to disease. Through remote work, in the labs with strict COVID safety protocols, and in partnership with personnel and patients at Virginia Mason, we kept our momentum of research making progress against everything from devastating viruses to Crohns disease to type 1 diabetes. |
| Form 990, Part III, Line 1 continued | Donor and NIH support of COVID Disease and Immune Response. For expertise in immunology research key to understanding symptoms caused by COVID-19, BRI received more than 5.8 million dollars from the National Institutes of Health NIH to fund studies involving lung tissue and COVID, immune response to the virus, and the phenomenon of cytokine storm. This funding would not have been possible without the support and confidence of our donors in giving more than 365,000 in seed money for initial research, enabling us to obtain larger government grants. Discoveries from BRI helped identify a new cellular protection pathway that targets a vulnerability common to several different pandemic viruses. Principal investigator Adam Lacy-Hulbert, PhD, was lead author on a study showing that this pathway can protect cells from infection by Ebola virus and coronaviruses, such as SARS-CoV-2. Published in Science, the findings provided a better understanding of cellular mechanisms involved in viral resistance to inform future treatments and therapies for infectious diseases. The research illuminated a completely new role for the two genes identified and a unique approach to inhibiting virus fusion and entry into human cells - bringing us one step closer to the next generation of antiviral therapies. A team collaboration with the University of Washington yielded evidence that mild cases of COVID-19 may trigger long-term immunity from the virus. The researchers, including Dan Campbell, PhD and Jessica Hamerman, PhD, performed an analysis of SARS-CoV-2 specific immune responses at one and three months following the onset of symptoms in patients who had recovered from mild COVID-19. Most of the participants developed antibodies, B and T cells that remained present for at least three months it appeared the recovered patients had formed virus-specific memory cells showing signs of antiviral immunity. |
| Form 990, Part III, Line 4 | One unique quality of BRI is the close integration of three types of medical research - laboratory research, translational research, and clinical research - to improve lives. Our scientists collaborate to explore basic science as well as clinical applications, which is the best way to design studies with the highest potential for success. At BRI, discovery starts in the laboratory but is driven by patient issues addressed in the clinic. |
| Form 990, Part III, Line 4a | 2020 advancements of the Immune Tolerance Network are highlighted as follows Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually support the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in three clinical areas asthma and allergic diseases autoimmune diseases and immune-mediated rejection of transplanted solid organs, tissues and cells. As the Prime recipient of this grant, BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2020 were diverse, but continued to center on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2020 include the following 1 Grant Renewal The ITN was notified in late 2020 that the ITN grant renewal had been awarded to Dr. Jerry Nepom at the Benaroya ReZsearch Institute. This is a 7-year, 189M award starting in 2021. 2 Cross Network Integration The COVID 19 pandemic in 2020 presented a temporary shift in ITN priorities as personnel spread across the ITNs three main operational sites moved to a work from home WFH model. This shift was largely seamless due to past focus on careful planning and emphasis on collaboration across the ITNs major centers, located in Seattle, San Francisco and Bethesda. No changes to existing network integration were needed as the current model continued to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. 3 Operations and Clinical Trial Support The ITN program team at BRI issued 211 sub-awards in 2020 in support of 22 active ITN clinical trials and numerous supporting ITN mechanistic trials. 4 Supplemental Funding / Partnerships ITN central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. In 2020, the ITN received supplemental funding as the contracting component for several NIAID sponsored COVID-19 clinical trials. a Supplemental Funding Opportunities The ITN Program Team at BRI submitted four supplemental funding requests in 2020. these requests were awarded, bringing in an additional 5.9M in funding to the ITN BRI. b Partnerships. The ITN continued its relationship with two pharmaceutical partners for partial funding on two ongoing ITN studies. NIAID is the clinical sponsor on both of these trials. 5 Publication Activity In 2020, 31 ITN publications were published in prestigious research journals and were presented at domestic and international research conferences. These publications represented ITN research in all therapeutic focus areas of the ITN Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. |
| Form 990, Part III, Line 4a continued | BRIs advances in Interventional Immunology research are highlighted as follows 1 Testing a vaccine for COVID-19. BRI served as one of about 150 Pfizer COVID-19 vaccine testing sites across six countries and 39 states. First, researchers opened enrollment for the trial and spread the word that they were looking for volunteers to participate in the study. Some participants received the vaccine, and others received a placebo. Frontline workers, several Virginia Mason ER doctors, and physicians from other local hospitals were among the volunteers. Led by Carla Greenbaum, MD, the research team had only three weeks to give the first vaccine dose to more than 80 participants - while social distancing meant they could have only a few people at a time in the Clinical Research Center. To make it happen, the team mapped out detailed schedules and worked nights and weekends. At the end of each day, they entered data about potential COVID-19 illnesses and vaccine side effects, which were monitored closely by Pfizer. When enough data had been collected worldwide, Pfizer announced its safety and efficacy endpoints had been met, and the FDA independently reviewed the data to decide whether to authorize the vaccine for emergency use. In late 2020, the research team finally got word from Pfizer that the FDA had approved the vaccine for use during the pandemic emergency. 2 A Strategy to Prevent Celiac Disease in Children. A study involving BRI scientists found that introducing high doses of gluten into infants diets could prevent them from developing celiac disease. Results from the Enquiring About Tolerance EAT study, published in JAMA Pediatrics, suggest this discovery could prove an effective prevention strategy for the disease. The EAT study investigated effects of gluten - in the form of wheat-based cereal - along with breastfeeding from the age of four months. Researchers compared the results with those from infants who avoided allergenic foods and consumed only breast milk until the age of six months. The results showed that among babies who delayed gluten introduction, celiac disease at three years of age developed at higher rates than expected. In contrast, there were no cases of the disease among children who had received gluten from four months of age. Celiac disease is an autoimmune disease in which eating gluten causes the bodys immune system to attack its own tissues, causing a range of potentially severe symptoms in the gut and elsewhere. 3 Type One Diabetes Research. BRI is dedicated to seeking ways to eliminate type 1 diabetes by finding ways to predict the disease before clinical symptoms occur and to identify therapies that prevent, reverse and intervene in the disease at any stage. BRI is an international leader in type 1 diabetes research and has investigated it for more than 30 years, starting with identification of a genetic marker for the disease. |
| Form 990, Part III, Line 4a continued | Advancements in 2020 included the following 1 BRI supports Type 1 Diabetes TrialNet, a National Institutes of Health-funded clinical trial network for type 1 diabetes prevention and early treatment, serving as the TrialNet hub of 18 clinical centers worldwide working with more than 150 screening and clinical research sites. 2 Immunotherapy Can Delay T1D - Carla Greenbaum, MD, chair of TrialNet, furthered findings that immunotherapy can delay a type 1 diabetes diagnosis in people at high risk. Findings from TrialNets Teplizumab anti-CD3 Prevention Study drawing from multiple sites showed the drug that targets the immune system can delay type 1 diabetes a median of two years in children and adults at high risk. Samples collected in the original trial were then studied to help Dr. Greenbaum and others understand why some people respond to the drug better than others - and how its benefits may be extended. Dr. Greenbaum, who in 2020 directed BRIs Diabetes Research Program and served as principal investigator for its TrialNet clinical site, noted the findings and additional insights represent great news for millions with T1D, as well as relatives who are at a high risk for the disease. 3 The TrialNet Pathway to Prevention study screens relatives of people with type 1 diabetes to find out if these family members are at risk for developing diabetes. Relatives of people with type 1 diabetes are at 15 times greater risk of developing type 1 diabetes. Those who qualify have the opportunity to enroll in a prevention trial. Those with two or more autoantibodies are closely monitored for early detection of type 1 diabetes. Close monitoring of at-risk family members can reduce the chances of being diagnosed in diabetic ketoacidosis DKA, a potentially life-threatening complication. 4 As home to the JDRF Core for Clinical Assay Validation CAV, BRI plays an important role in identifying type 1 diabetes biomarkers and in helping outside researchers get the most accurate test results. The CAV is pinpointing key biomarkers, such as those indicating which patients will keep making insulin for years and which patients wont. The CAV also helps maintain quality control for a worldwide network of research labs by asking them to perform specific tests and reviewing their results. |
| Form 990, Part III, Line 4b | Translational Immunology research observations are made in the basic research lab, then quickly tested in the clinic with patients, with results brought back to the lab again in an expedient and systematic way. This type of research translates new methods to improve our ability to predict disease risk, prevent onset of disease, slow disease progression and improve safety and efficacy of treatments. At BRI, translational research addresses autoimmune and immune-mediated diseases. The BRI biorepository is a collection of blood, serum and tissue samples, as well as medical histories, from volunteers with and without diseases involving the immune system. BRI scientists and physician collaborators work together to study tissue, blood and serum samples along with the medical and demographic data. BRIs biorepository samples date back to 2000 and include multiple disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2020 included the following 1 Sound Life Project - BRI completed volunteer enrollment for this study in which researchers are tracking healthy immune systems over time. Seattle-area adults in two age cohorts - 25-35 and 55-65 - are participating in this groundbreaking study to build a baseline of knowledge about the human immune system to understand disease. The goal is to lay the groundwork for better ways to diagnose, treat and prevent immune system diseases such as rheumatoid arthritis, type 1 diabetes and multiple sclerosis. Volunteers provide blood samples and health information through in-person visits and a phone app developed at BRI, allowing researchers to track their immune systems over the course of two years. The project is the initial phase of a research partnership with the Allen Institute for Immunology. BRI is providing detailed information about healthy immune systems to serve as a foundation for existing and future disease research programs. 2 Autoimmune Disease Research in the Down Syndrome Population. BRIs Bernard Khor, MD, PhD, and Virginia Mason pediatrician Rebecca Partridge, MD, continued their work leveraging a grant from the National Institutes of Health to build a Down syndrome DS biorepository to research the connection between DS and autoimmune disease. The collection includes blood, serum and tissue samples, as well as medical histories, from volunteers, people with DS and their relatives, with and without autoimmune diseases. The DS population has long been underrepresented in medical research, as nearly 50 percent of this population is living with at least one autoimmune disease. BRI is among the first to be awarded a grant dedicated to autoimmune disease in the DS population. 3 Type 1 Diabetes Fast Progressors and Prevention Strategies - Alice Long, PhD, and colleagues pursued their landmark discovery that is leading to new treatment strategies for type 1 diabetes T1D. In some people newly diagnosed with the disease, it progresses so quickly that their pancreas stops making insulin within a year. For others, the process is slower and this can make the disease easier to manage. The researchers discovery enables early identification of fast progressors to potentially match them with treatments to help them stay healthier for much longer. The researchers identified important differences between fast progressors and people whose disease progresses slowly. Dr. Longs team showed that slow progressors have higher levels of exhausted CD8 T cells - cells that are worn out from attacking the pancreas. The discovery could lead to a test that identifies how quickly individual patients will lose their ability to make insulin. Then, Dr. Long received additional funding to investigate why CD8 T cells become exhausted. For people with T1D, a therapy that would slow down or even stop attacker cells would prolong their ability to make insulin, which makes their lives much easier and significantly reduces their long-term health risks. Peter Linsley, PhD, led BRIs bioinformatics team in helping to analyze a vast amount of data from the cells. While researchers are typically only able to look at two or three aspects of each cell, Dr. Linsleys team used innovative technology to help Dr. Long and colleagues collect and analyze data on up to 30 aspects of each cell. 4 In 2020, BRI also received a 5.4 million contract award from the NIH to improve treatments for patients diagnosed with rheumatoid arthritis. |
| Form 990, Part III, Line 4c | 1 Fundamental Immunology The Center for Fundamental Immunology investigates the immune system to understand how it works in health and disease. At BRI, we employ a variety of methods to examine the immune system function at the genetic, molecular and cellular levels. These include developing novel model systems of autoimmune and inflammatory disease, used to determine how activities of the immune system are regulated and how regulatory mechanisms break down in autoimmunity, allergy, asthma and COVID-19. We also leverage samples from healthy subjects and patients with immune-mediated diseases to study immune system function and identify potential therapeutic targets. 2 Systems Immunology With the explosion of data from genome studies and molecular profiling technologies, huge amounts of biological information are now available. BRI scientists in this Center use complex systems theory and high throughput techniques as well as mathematical and computational tools to understand the functioning of the immune system in health and disease. |
| Form 990, Part III, Line 4d | BRI oversees the Clinical Research Program at Virginia Mason Medical Center, uniquely combining the expertise of a world-renowned medical research institute with the care of a healthcare quality leader. The Clinical Research Program supports Virginia Mason clinical investigators in studies across a wide variety of autoimmune and immune-mediated diseases and conditions, as well as a broad range of other diseases such as cancer and cardiac disease. The Clinical Research Program staff annually enrolls approximately 1500 study participants into Virginia Mason trials, but numbers were fewer in year 2020 due to the pandemic. 1 Testing a New MS Therapy - a research study at BRI and Virginia Mason is seeking to find out if an experimental oral drug, similar to a currently available MS medication, would be just as effective as the current one, but with fewer gastrointestinal side effects. In an earlier study, half the research participants took this experimental drug and half took the current drug. Participants who finished the five-week study then enrolled in a two-year study of the experimental drug. |
| Form 990, Part VI, Section A, Line 1a | The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The President and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all of the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. |
| Form 990, Part VI, Section A, Line 4 | Effective January 1, 2021 Franciscan Health System FHS, Virginia Mason Health System VMHS, and CommonSpirit HealthCommonSpirit, a member of FHS, completed the affiliation transaction the Affiliation contemplated by the Affiliation Agreement, dated as of December 31, 2020, pursuant to which, among other things, CommonSpirit formed Virginia Mason Franciscan Health, a Washington nonprofit corporation VMFH. After the effective date, CommonSpirit and VMHS are the sole corporate members of VMFH, which is a controlleld subsidiary of CommonSpirit and will be consolidated with CommonSpirit for accounting purposes. As a result of the Affiliation, VMFH now governs and manages the combined operations of FHS, Virginia Mason Medical Center VMMC Benaroya Research Institue BRI, and certain other affiliates of FHS and VMMC the Combined System, subject to certain VMHS protective reserved powers and other reserved powers held by CommonSpirit and VMFH is now the sole corporate member of both VMMC and BRI. |
| Form 990, Part VI, Section A, Line 6,7 | Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. |
| Form 990, Part VI, Section B, Line 11b | The Form 990 tax return is reviewed by the BRI advisory Finance Committee and the BRI advisory Board prior to filing. The final Form 990 return is provided to each member of the advisory Board via electronic delivery. |
| Form 990, Part VI, Section B, Line 12c | The VMHS Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Management Plan be maintained. |
| Form 990, Part VI, Section B, Line 15 | The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee Executive consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2020 were Jane Buckner, BRI President and Director, Carla Greenbaum, BRI Director, Steven Ziegler, Director, Academic Affairs, Michael Labosier, Chief Financial Officer, and Margaret McCormick, Executive Director and Chief Operating Officer. |
| Form 990, Part VI, Section C, Line 19 | The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. |
| Software ID: | 20011406 |
| Software Version: | 20.0.2.0 |
|
Affiliated Group Business Name:
Benaroya Research Institute at Virginia Mason
Address. Either US or Foreign Type:
1200 Ninth Avenue
Seattle, WA98101 EIN:
91-0653422
Electing Organization Checkbox:
Total Grassroots Lobbying:
0
Total Direct Lobbying:
0
Total Lobbying Expenditures:
0
Other Exempt Purpose Expenditures:
71,349,522
Total Exempt Purpose Expenditures:
71,349,522
Lobbying Nontaxable Amount:
57,878
Grassroots Nontaxable Amount:
14,470
Tot Lobbying Grassroot Minus Non Tx:
0
Tot Lobby Expend Mns Lobbying Non Tx:
0
Share Of Excess Lobbying:
|
|
Affiliated Group Business Name:
Virginia Mason Medical Center
Address. Either US or Foreign Type:
1100 Ninth Avenue
Seattle, WA98101 EIN:
91-0565539
Electing Organization Checkbox:
Total Grassroots Lobbying:
129,023
Total Direct Lobbying:
80,424
Total Lobbying Expenditures:
209,447
Other Exempt Purpose Expenditures:
1,140,696,406
Total Exempt Purpose Expenditures:
1,140,905,853
Lobbying Nontaxable Amount:
925,495
Grassroots Nontaxable Amount:
231,373
Tot Lobbying Grassroot Minus Non Tx:
0
Tot Lobby Expend Mns Lobbying Non Tx:
0
Share Of Excess Lobbying:
|
|
Affiliated Group Business Name:
Virginia Mason Institute
Address. Either US or Foreign Type:
1100 Ninth Avenue
Seattle, WA98101 EIN:
26-3763656
Electing Organization Checkbox:
Total Grassroots Lobbying:
0
Total Direct Lobbying:
0
Total Lobbying Expenditures:
0
Other Exempt Purpose Expenditures:
3,869,715
Total Exempt Purpose Expenditures:
3,869,715
Lobbying Nontaxable Amount:
3,139
Grassroots Nontaxable Amount:
785
Tot Lobbying Grassroot Minus Non Tx:
0
Tot Lobby Expend Mns Lobbying Non Tx:
0
Share Of Excess Lobbying:
|
|
Affiliated Group Business Name:
Virginia Mason Health System
Address. Either US or Foreign Type:
1100 Ninth Avenue
Seattle, WA98101 EIN:
91-1351110
Electing Organization Checkbox:
Total Grassroots Lobbying:
0
Total Direct Lobbying:
0
Total Lobbying Expenditures:
0
Other Exempt Purpose Expenditures:
16,626,427
Total Exempt Purpose Expenditures:
16,626,427
Lobbying Nontaxable Amount:
13,487
Grassroots Nontaxable Amount:
3,372
Tot Lobbying Grassroot Minus Non Tx:
0
Tot Lobby Expend Mns Lobbying Non Tx:
0
Share Of Excess Lobbying:
|